Allarity Therapeutics Stock Alpha and Beta Analysis
| ALLR Stock | USD 1.10 0.01 0.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Allarity Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Allarity Therapeutics over a specified time horizon. Remember, high Allarity Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Allarity Therapeutics' market risk premium analysis include:
Beta 1.05 | Alpha (2.09) | Risk 7.27 | Sharpe Ratio (0.29) | Expected Return (2.09) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Allarity |
Allarity Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Allarity Therapeutics market risk premium is the additional return an investor will receive from holding Allarity Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Allarity Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Allarity Therapeutics' performance over market.| α | -2.09 | β | 1.05 |
Allarity Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Allarity Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Allarity Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Allarity Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Allarity Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Allarity Therapeutics shares will generate the highest return on investment. By understating and applying Allarity Therapeutics stock market price indicators, traders can identify Allarity Therapeutics position entry and exit signals to maximize returns.
Allarity Therapeutics Return and Market Media
The median price of Allarity Therapeutics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 1.64 with a coefficient of variation of 55.82. The daily time series for the period is distributed with a sample standard deviation of 1.23, arithmetic mean of 2.21, and mean deviation of 0.95. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Alexander Epshinsky of Allarity Therapeutics subject to Rule 16b-3 | 09/12/2024 |
2 | ALLR INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class ... | 09/19/2024 |
3 | The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc. | 09/27/2024 |
4 | INVESTOR DEADLINE APPROACHING Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - Markets Insider | 10/08/2024 |
5 | Allarity Therapeutics to be Granted European Patent for DRP Companion Diagnostic for Stenoparib | 10/22/2024 |
6 | The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud | 10/29/2024 |
7 | The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud | 11/06/2024 |
8 | ALLR Deadline ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit | 11/08/2024 |
9 | FINAL DEADLINE ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics | 11/12/2024 |
10 | Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate ... | 11/18/2024 |
11 | Allarity Therapeutics Provides Corporate Update in Recent Press Release | 11/22/2024 |
About Allarity Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Allarity or other stocks. Alpha measures the amount that position in Allarity Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 0.0136 | 0.013 | Receivables Turnover | 0.0651 | 0.0579 |
Allarity Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Allarity Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allarity Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Allarity Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Allarity Therapeutics. Please utilize our Beneish M Score to check the likelihood of Allarity Therapeutics' management manipulating its earnings.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Allarity Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.